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Human NADH-ubiquinione oxidoreductase defi-
ciency can be present in a wide variety of biochemi-
cal and symptomatic phenotypes. In fact, the ob-
served spectrum of severity varies from fatal infantile
lactic acidosis to adult onset exercise intolerance or
optic neuropathy. Since most genetic diseases display
a much more narrow set of indices, perhaps this wide
variety of clinical presentation requires some expla-
nation. Many of the problems that revolve around the
diagnosis of Complex I defects stem from the fact
that Complex I is a huge multienzyme complex of 41
separately encoded gene products derived from both
w xnuclear and mitochondrial genomes 1,2 . This dual
coding system leads to a number of difficulties,
misconceptions and pitfalls surrounding etiology and
diagnosis. In addition, a further complicating factor
related to oxygen free radical generation seems to be
an important factor in the determination of pathology
in affected individuals.
1. Basic principles—the biology of Complex I
Though Complex I NADH-ubiquinone oxido-
.reductase in mammalian mitochondria appears to
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contain at least 41 distinct proteins, it is not known
how many of them are involved directly in transport
of electrons coupled to vectorial proton movements.
The proteins of Complex I are traditionally divided
 .  .up into flavoprotein FP , iron protein IP and hy-
 . w xdrophobic protein HP fractions 1,2 . Mitochondria
of higher animals have seven mitochondrially en-
coded proteins in Complex I that are intricately asso-
ciated with the inner mitochondrial membrane and
w xare part of the HP fraction 3 . Based on the elbow or
boomerang shape of Complex I observed by electron
microscopy for the Neurospora crassa complex, the
subfractionation profiles of mammalian Complex I
and the homology to bacterial hydrogenase and dehy-
drogenase complexes, a possible arrangement of the
 . w xmajor subunits can be predicted Fig. 1 4–9 . The
passage of electrons goes through an FMN centre
located in the 51 kDa protein, then through a 4Fe–4S
centre on the same protein, through a 2Fe–2S centre
in the 24 kDa protein, a 4Fe–4S centre in the 75 kDa
protein and then probably through iron–sulfur centres
w xon the 20 kDa and 23 kDa subunits 9,10 . The final
acceptor of the electrons is ubiquinone although there
is evidence that at least two quinone acceptance loci
exist with different sensitivity to quinone analogue
w xinhibitors 11–13 . The reaction mechanism whereby
electron transfer is coupled to vectorial proton
w xtranslocation is not clear 10 . There is evidence that
a high titre of semiquinone radical is produced within
Complex I and that this semiquinone is an integral
0005-2728r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
 .PII S0005-2728 98 00033-4
( )B.H. RobinsonrBiochimica et Biophysica Acta 1364 1998 271–286272
Fig. 1. Complex I of the mitochondrial respiratory chain. The complex is depicted as an elbow shaped assembly with one arm facing into
the matrix and the other arm being associated with inner mitochondrial membrane. The subunits considered to be involved in the transport
of electrons are the 51 K flavoprotein containing a 4Fe–4S centre, with the 24 K, 75 K, 23 K and 20 K iron sulfur proteins. Two quinone
reduction sites are postulated. The mtDNA-encoded subunits are all part of the membrane arm of the complex and some of them are
possibly involved in proton pumping functions.
w xpart of the reaction mechanism 14,15 . In order to
produce vectorial proton movement via the move-
ment of electrons it is probable that the FeS centres
associated with the membrane arm of the complex,
i.e., the two centres in the 23 kDa TYKY subunit,
catalyse a vectorial movement of protons coupled to
w xsemiquinone oxidationrreduction 10 . This becomes
important later in the consideration of free radical
production in patients with Complex I deficiency.
2. The supernumery subunits
Only one of the mtDNA encoded subunits appears
to have a defined role. The ND1 subunit has been
shown to be the binding site for both rotenone and
for photoaffinity-labelled ubiquinone analogues, sug-
gesting that this is the terminal acceptor for quinone
reduction within the membrane portion of Complex I
w x13,16 . The function of the remaining six mtDNA
encoded subunits remains obscure, though there are
some important clues from the patients affected with
mutations in the ND subunits. It has been demon-
strated that patients with mutations in the ND1 gene
have defective electron transport while patients with
ND4 defects have no such defect but are unable to
carry out ATP synthesis from NAD linked substrates
w xin isolated mitochondria 17 . This implies that a
coupling function such as proton translocation is
impaired in ND4 mutations. Since ND2, ND4 and
ND5 possess a certain amount of homology, it is not
unreasonable to propose that these three subunits are
w xall involved in proton transport in some way 18 .
The ND6 subunit is probably also involved in elec-
tron transport events since mutations in this subunit
w xaffect electron flow in Complex I 18,19 .
Of the 34 nuclear encoded subunits in the bovine
complex, the 75, 51, 49, 30, 24, 23 and 20 kDa
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subunits are equivalent to proteins present in bacterial
w xComplex I 3 . There are another 27 proteins in the
mammalian complex as identified by Walker and
w xothers 20–33 . These proteins are unusual in that
nine of them have blocked N-termini and no leader
sequence for import, while another nine proteins have
no leader but an open N-terminus. Another nine have
the more expected cleavable leader sequence desig-
nating import into the matrix. The majority of the
leaderless peptides appear to be part of the hydropho-
 .bic membrane fraction Table 1 .
Few functions have been assigned to the supernu-
mery subunits not held in common with Paracoccus.
The SDAP protein, a small 10 kDa protein with
homology to acyl carrier proteins, appears to have a
function in mitochondrial phospholipid metabolism
w x40 and its removal in yeast and Neurospora seems
to impair a number of mitochondrial functions as the
intramitochondrial lysophospholipid content is in-
creased. The phosphorylation of at least four subunits
of Complex I have been described, namely the 42
kDa, 29 kDa, 18 kDa AQDQ subunit and the MWFE
Table 1
Nuclear-encoded subunits of Complex I
Name M Leader N-terminus Function Chromosome Referencesr
w x75 K FeS 75 q 4Fe–4S 2q33–34 21,22
w x51 K Fp 51 q Flavin, 4Fe–4S 11q13 25,34
w x49 K 49 q y Chr 1 26,35
w x42 K 42 q y y 30
w x39 K 39 q Phosphorylation 12p 30
w x30 K 30 q y y 27
w x24 K FeS 24 q 2Fe–2S 18p11.3 27
 . w x23 K FeS TYKY 23 q 4Fe–4S 11q13 36
w xB22 22 y N-Acetyl y 8q13.3 37
w xPSST 20 q 3Fe–3S 19p13.2 29,38
w xPDSW 22 y y 31
w xPGIV 19 y y y 28
w xASH 1 18 q Phosphorylation? y 33
w xSGDH 18 q y y 33
w xB18 18 y N-Myristoyl Phosphorylation? y 33
 . w x18KIP AQDQ 18 q Phosphorylation? y 33
w xB17 17 y N-Acetyl y y 33
w xB15 15 y N-Acetyl y y 33
 . w xB14.5a ASAT 14.5 y Q-binding 17 24
 . w xB14.5b MMTG 14.5 y y y 24
w xB14 14 y N-Acetyl y y 33
w xB13 13 y N-Acetyl y y 33
 . w x15 K 1P 15 y y 33
w xB12 12 y Unknown Mod y y 33
w xB8 8 y N-Acetyl y y 33
 . . w x13 K 1P DDGD 13 q y y 33
w xMLRQ 9 y y y 33
w xB9 9 y Unknown Mod y y 33
w xAGGG 10 q y y 33
w xMWFE 6 y Phosphorylation Xq24 33,39
w xMNLL 5.5 y y y 33
w xKFY1 5 y y y 33
 . . w x10 K 1P SHES 10 q y y 32
w x5DAP 10 y Acyl Carrier Protein y 22
References are given for the subunit determined from Bostaurus, except for those with chromosomal allocations which have human
cDNA clones reported. See text for details.
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w xsubunit 41 . Two of these proteins, namely the 18
kDa AQDQ and the MWFE have been shown to be
phosphorylated by cyclic AMP dependent kinase
w x41,42 . While there is some evidence that there is a
cyclic AMP dependent kinase activity which is mito-
chondrial in location, it almost certainly resides on
w xthe outer membrane 43 . It is not clear what phos-
phorylation does to the activity of Complex I. It
seems that these subunits can be phosphorylated in an
atractyloside sensitive manner in whole mitochondria,
w xbut to what purpose is not clear at this time 44,45 .
2.1. Chromosomal allocation
We and others have isolated human cDNA clones
for the 51 kDa flavoprotein, the 75 kDa Fe2qS
protein, the 39 kDa, 24 kDa, the B22, the 20 kDa
Fe2qS protein, the 14.5 kDa and 6 kDa protein and
mapped them by in situ hybridization to chromosome
w xspreads 21–23,38,34,35,46,36,37,39 . Since there are
few if any families with X-linked Complex I defi-
ciency, these allocations are not particularly helpful,
but it is possible that a patient with a chromosomal
rearrangement and Complex I deficiency may lead to
 .the definition of the gene s responsible for this
defect.
3. Diagnosis of Complex I deficiency
3.1. Nuclear-encoded defects in Complex I
Isolated Complex I deficiency appears to be an
autosomal, or possibly in a few cases, an X-linked
disease in which patients can suffer from a wide
w xconstellation of symptoms 37,39,47 . In the first case
w xreported, the case of Moreadith et al. 48 , e.s.r.
analysis of muscle mitochondria showed an Fe2qS
w xprotein to be reduced 49 . We showed that the defect
was not as pronounced in cultured skin fibroblast
mitochondria from this patient but was detectable by
w xthe altered redox state of the cells 35 . A second case
w xdescribed by Hoppel et al. 50 also died in infancy
and was demonstrated to have deficient rotenone-sen-
sitive NADH cytochrome c reductase and NADH
duroquinone reductase in liver mitochondria, muscle
mitochondria and skin fibroblasts. These two patients
at autopsy showed evidence of mitochondrial prolif-
eration, ventricular cardiomyopathy and spongy de-
generation of the brain. Both had a chronically raised
level of blood lactate with intermittent severe acido-
sis. Two very well documented patients described by
w xFujii et al. 51 with Leigh disease had muscle Com-
plex I deficiency. Both infants displayed damage to
the putamen, thalamus and substantia nigra on CT
scan of the brain. This agreed with data we reported
on 24 patients exhibiting Complex I deficiency, half
of which had Leigh disease with possible associated
w xcardiomyopathy 47,52 . More recently Turnbull’s
group in Newcastle and Thorburn’s group in Mel-
bourne has confirmed our findings that isolated Com-
plex I deficiency is the most common mitochondrial
w xrespiratory chain defect 53,54 .
Our ability to identify large numbers of patients
with Complex I deficiency stems from a screening
test we perfected some 12 yr ago. The screening test
we invented to identify fibroblast cultures with respi-
ratory chain defects depends on the measurement of
lactate to pyruvate ratio after incubation of the cells
w xwith glucose for a one hour period 55–57 . We
showed that for both cytochrome oxidase deficiency
and Complex I defects there is a relationship between
the residual activity of the enzyme and the LrP ratio
w x9,47 . This test does not detect mtDNA derived
respiratory chain defects except in rather unusual
 o .circumstances r or mtDNA depleted fibroblasts
and is particularly useful in the case of Complex I
deficiency which is not easy to demonstrate in cul-
tured cell systems by enzyme analysis. This is largely
because of heteroplasmy so that the abnormal redox
state is not expressed unless % mutant mtDNA goes
w xabove 85% or 90% 47,57,58 .
Correlation of the LrP ratios and clinical data and
data from clinical descriptions of Complex I defi-
ciency diagnosed in muscle has led to the classifica-
 . w xtions shown below Table 2 47,52–54 . Our study
of Complex I defects has also shown us that muscle
mitochondria will often show severely deficient
rotenone-sensitive NADH-cytochrome c reductase,
while fibroblast mitochondria exhibit a less pro-
w xnounced deficiency 47 . Despite the less pronounced
deficiency in fibroblast mitochondria, the defect is
w xusually manifest in a high LrP ratio 9,47 . The
clinical spectrum of patients exhibiting Complex I
deficiency as judged by the above criteria is a wide
one. The clinical course we found to be most com-
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Table 2
The clinical presentation of isolated Complex I deficiency in 60 patients
Incidence Major features Number of patients
 .Most common Leigh’s disease"cardiomyopathy WPW or progressive deterioration—slowrfast 35
Fairly common Fatal infantile lactic acidosis cystic changes in white matter 15
Uncommon Hepatopathy and tubulopathy 4
Cardiomyopathy and cataracts 2
Cataracts and developmental delay 2
Neonatal lactic acidemia 2
Normal development
mon was that of Leigh disease with onset from three
w xmonths to ten years of age 47,56 . The patient’s
muscle exhibits mitochondrial hypertrophy but true
ragged red fibres are rarely seen. We found a consid-
erable incidence of ventricular cardiomyopathy ;
.40% in patients with Complex I defects not seen in
w xother patients with Leigh disease 47,56 . All of these
patients were tested for the mtDNA mutations re-
sponsible for MERRF and MELAS and for mutations
in other mitochondrial tRNAs but no cell lines were
positive. The information gathered from families with
Complex I deficiency showed that there were equal
numbers of males and females affected, the pattern
being suggestive of autosomal recessive disease with
w xpossibly a few cases being X-linked 47,56 . A sec-
ond category frequently seen is fatal neonatal lactic
acidosis, where the patient has such a severe defect
that the acidosis that results from the lactic acid
production exceeds the buffering capacity of the body
w x47,59,60 . Severe cases of Complex I deficiency
were found by Western blotting not to assemble
w xComplex I 47 . More recently we described three
less common categories: the presentations of those
patients with hepatopathy and tubulopathy, those with
very mild symptoms such as exercise intolerance, and
w xthose with cardiomyopathy and cataracts 52 . In the
first category there is an unusual involvement of the
liver and kidney sometimes accompanied by neurode-
generation. In the second category there is normal
development but with some exercise intolerance and
w xsometimes congenital cataracts 52 . The third is de-
scribed below. Western blots with anti-Complex I
antibody failed to show reproducible differences spe-
cific to any one subunit, though the display of cross-
reacting subunits is limited to eight or nine proteins
w x47,52 . Techniques using Native Blue PAGE fol-
lowed by SDSrPAGE in the second dimension have
been more recently developed which resolve more
w xthan 20 subunits of Complex I 61 . The technique
was used to show a reduction in several Complex I
subunits in a case of Complex I deficiency with lactic
acidosis, cerebellar cystic lesions and hypertrophic
w xcardiomyopathy 62 . There is some correlation be-
tween the redox state of cells measured by LrP ratio
and the magnitude of depression of NADH-cyto-
 .chrome c reductase Fig. 2 for Complex I deficient
patients but this is a rather loose association and does
w xnot account for clinical severity of the disease 52 .
3.2. The syndrome of cardiomyopathy and cataracts
 .McKusick entry 212 350 lists a number of cases
in which bilateral congenital cataracts are associated
 .with hypertrophic ventricular cardiomyopathy HC ,
exercise-induced hyperlactatemia and mitochondrial
w xmyopathy 64 . Three unrelated sibships produced
seven affected children out of 22 in which symptoms
w xof varying severity were apparent 65–67 . Again,
there was no CNS involvement but many affected
family members had chronic progressive cardiomy-
opathy with early death as the endpoint. We have
studied a kindred from Alberta who produced three
such affected children in a double cousin marriage.
They had congenital cataracts, cardiomyopathy and
w xchronic lactic acidemia 68 . Inheritance pattern in
these families is consistent with an autosomal reces-
sive gene, and paternal transmission rules out any
role of mitochondrial DNA. We have shown that in
skin fibroblasts from affected family members, there
is a problem affecting the redox state of the mito-
chondria at the level of Complex I NADH-CoQ
. w xreductase 69 . We also have good evidence that this
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Fig. 2. Dependence of lactate to pyruvate ratio on the residual activity of complex Iq III. Fibroblast mitochondrial NADH-cytochrome c
 .reductase rotenone-sensitive is plotted as a function of the observed lactate to pyruvate ratio in the whole cell cultures. Data from Ref.
w x63 .
effective blockage within Complex I leads to an
excessive rate of free radical production and hyper-
sensitivity of the cell cultures to toxicity from mena-
w xdione and other free radical amplification agents 59 .
We showed that the presence of unusual lipid alco-
hols resulting from peroxidation of lipids in these
cells is also another indicator of free radical damage
w x64 . We recently showed that a massive induction of
the mitochondrial Mn2q superoxide dismutase takes
w xplace in these cells 66 .
3.3. Defects encoded in mtDNA
There has been a substantial increase in our knowl-
edge of how deletions, duplications and point muta-
tions in mtDNA can influence the expression of the
w xcomponents of the respiratory chain 9 . There are
basically two ways in which mitochondrial DNA
defects can produce disease: by interference with the
process of mitochondrial protein synthesis, and by
interference at specific sites in the process of oxida-
tive phosphorylation. Both can give rise to measur-
able defects in Complex I in muscle mitochondria.
In the former group the proliferation of subsar-
colemnal mitochondria gives muscle histology a
characteristic appearance with the Gomori trichrome
stain such that a proportion of the fibres appeared to
be stained red around the periphery and the fibre
w xmargin appears to be convoluted 70–72 . These fi-
bres are called ‘ragged red fibres’ and only a small
group of diseases characteristically display this form
of muscle pathology. The differential diagnosis for
these ragged red fibre diseases is complex because
they usually involve systems other than skeletal mus-
cle, usually components of the central nervous system
w x72 . The ragged red fibre diseases that have been
reported as having respiratory chain defects are:
mitochondrial encephalomyelopathy with lactic aci-
 .dosis and stroke-like episodes MELAS , myoclonus
 .epilepsy with ragged red fibres MERRF , Kearns–
 .Sayre syndrome KSS , chronic progressive external
 .ophthalmoplegia CPEO , myopathy and cardiomy-
 .  .opathy MMC and mitochondrial myopathy MM
w x70 .
This group of diseases has now been well charac-
terized at the molecular level and involves point
mutations in mitochondrially-encoded tRNA species
for leucine and isoleucine in the case of MELAS,
tRNA for lysine in the case of MERRF and major
mtDNA deletions in the case of Kearns–Sayre or
w xCPEO 73–77 . This group of diseases has recently
w xbeen reviewed by Wallace 73 and many of them
show either a decrease in Complex I activity, Com-
w xplex IV activity or both 78–80 . The mechanism
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related to the relative decrease in respiratory chain
complexes depends very much on the species of
tRNA affected and the contribution of that tRNA to
the synthesis of mtDNA encoded polypeptides of the
respiratory chain. Thus mutations in the tRNALeuUUR.
produce major Complex I defects in the muscle of
affected patients because of the high titre of leucines
w xencoded in the ND subunits of Complex I 81 . On
the other hand, mutation of tRNAGly at 9997 produces
mainly Complex IV deficiency because of the high
titre of glycines in the cytochrome oxidase subunits I,
w xII and III 82 . Such influences plus the distribution
of heteroplasmy of the mutation in various tissues
leads to rather different phenotypes which depend on
the tRNA involved. Several tRNALeuUUR. mutations
give rise to MELAS while the tRNAGly mutation
produces a hypertrophic ventricular cardiomyopathy
 . LeuUUR.HVCM . Some tRNA mutations can produce
also an HVCM or a mitochondrial myopathy alone
and the reasons for this are not completely under-
w xstood 73,83 .
A number of point mutations in the mtDNA re-
gions encoding respiratory chain polypeptides have
been found to be present in patients with Lebers
 .Hereditary Optic Neuropathy LHON . While the
majority of patients have a mutation at 11 778 in
w xND4 which changes an Arg to a His 73 , other
 .mutations have been found which affect ND1 3460
 . w x w xor ND6 14 484 84 , cytochrome b 73 and cy-
w xtochrome oxidase 85 . While none of these patients
show ragged red fibre disease or lactic acidemia, they
show that the same clinical phenotype can result from
the impairment of the respiratory chain at several
different sites. It is also established that LHON is
maternally inherited. In contrast to the mutation af-
fecting ND4 which does not produce any measurable
change in NADH-CoQ reductase activity, both the
ND6 and the ND1 mutation shows considerably re-
w xduced activity 86 . All three defects, however, show
impaired rates of ATP synthesis by isolated mito-
chondria indicating that ND4 is probably involved in
w xcoupling electron flow to ATP synthesis 86 .
 .The implications of these findings are that: 1
there can be deleterious mutations in Complex I
which are subtle and are without detectable changes
in enzyme activity and without the patient displaying
 .lactic acidemia, 2 there may be Complex I genetic
defects that phenotypically do not resemble other
mitochondrial diseases. Two more deleterious muta-
tions have now been described, one in ND4 at 11 696
and one in ND6 at 14 459 which in addition to
LHON produce in some family members the clinical
symptoms of dystonia with accompanying lesions in
w xthe caudate and putamen visible on MRI 87,88 .
These mutations present in the heteroplasmic state
can cause depressed rates of ATP synthesis and
w xelectron transport in isolated mitochondria 87,88 .
Those family members with high percentages of mu-
tant mtDNA showed more severe symptoms and an
earlier age of onset.
3.4. Free radical generation by the respiratory chain
It has been known for some time that free radicals,
especially the superoxide ion Oy, are generated by2
respiratory chain activity. Indeed, it has been esti-
mated that the fate of 1%–2% of all electrons passing
down the electron transport chain is to be diverted
w xinto the formation of superoxide radicals 89 . Interest
has been stimulated by the discovery that free radical
generation may be involved in selective cell death
 .apoptosis and that radicals generated from the respi-
w xratory chain contribute to this 90 . Indeed mitochon-
drial changes are central to several modes of apopto-
sis. Superoxide itself probably arises from interaction
between molecular oxygen and a species of
 .semiquinone UQ which is a natural intermediate10
in one electron reduction events in electron transport
w xthrough Complexes I and III 89 . Little is known
about the processes that are involved in this genera-
tion of superoxide though it is reasonable to guess
that it occurs at the juxtaposition of an electron
carrier such as an FeS protein and a site of quinone
reduction within the respiratory chain complexes
w x91,92 . Semiquinone radicals generated in the vicin-
ity of the TYKY 23 kDa FeS protein would be a
prime candidate as electron donors for superoxide
formation. It is not known how such a process is
controlled at high and low respiration rates, what the
sidedness is of the process with respect to the mito-
chondrial membrane and how excessive superoxide
production is set in motion in response to cytokines.
These questions are awaiting resolution.
Removal of free radicals generated in the course of
normal electron transport is obligatory if cellular
damage is to be avoided. Superoxide is removed by
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the enzyme Mn2q superoxide dismutase which is
mitochondrial, and Cu2q Zn2q superoxide dismutase
which is extramitochondrial and also exists in an
w xextracellular form 79,63 . Both superoxide dismu-
tases produce hydrogen peroxide which unlike super-
oxide is probably diffusable across biological mem-
branes and is reasonably stable. Thus hydrogen per-
oxide produced both inside and outside of the inner
mitochondrial membrane can be removed by the ac-
tivity of either catalase or glutathione peroxidase
 .Fig. 3 . Dependence on the latter enzyme may then
be linked to the availability of glutathione. While we
have concentrated our efforts on defining the role of
w xMnSOD 63 it is possible that respiratory chain free
radical production is relevant to other genetic defects
where superoxide dismutase is involved, such as
trisomy 21 and Amyotrophic Lateral Sclerosis. It has
been suggested that pathophysiological events result
in these cases from over-activity of CuZnSOD partic-
ularly in the reverse direction where mutant CuZn-
SOD can catalyse formation of hydroxyl radical from
hydrogen peroxide generated in the mitochondria. We
.therefore found it of interest to investigate: a whether
superoxide is produced in excess in patients who
.have defects within Complex I, and b whether these
free radicals generated actually participate in produc-
ing cell damage and cell death in the individuals
w xaffected 69,63 .
3.5. Free radical production in Complex I deficiency
We then went on to examine mitochondria isolated
from cultured skin fibroblasts from healthy individu-
 . als controls and patients with Complex I NADH-
.CoQ reductase deficiency of the mitochondrial respi-
ratory chain. The patients included those with fatal
 .infantile lactic acidosis FILA , cardiomyopathy with
 .  .cataracts CC , hepatopathy with tubulopathy HT ,
 .Leigh disease LD , cataracts and developmental de-
 .lay CD , and lactic acidemia in the neonatal period
 .followed by mild symptoms MS . Production of
superoxide radicals were measured using the lumino-
metric probe lucigenin with isolated fibroblast mito-
w xchondrial membranes on addition of NADH 69,63 .
Superoxide production rates were highest with CD
and decreased in the order CD 4 MS ) LD )
w x  .CONTROL)HT)FILAsCC 63 Fig. 4 . Quan-
 .tity of Mn superoxide dismutase MnSOD , as mea-
sured by Elisa techniques, MnSOD activity and
Northern blots, however, was highest in CC and
w xFILA and lowest in CD 63 . The induction of Mn-
SOD appeared to be a function of the disturbance in
Fig. 3. Relationship between superoxide production by the respiratory chain and xanthine oxidase to its disposal. Superoxide can be
 .  .removed by either manganese superoxide dismutase MnSOD or copper zinc superoxide dismutase CuZnSOD to produce hydrogen
peroxide which is then removed by catalase or glutathione peroxidase. The two compartments are depicted as the inside of the
 .  .mitochondrial matrix space in and the space outside of the mitochondrial matrix out . When superoxide production exceeds the capacity
of MnSOD to remove it, damage to FeS centres may result in releasing free iron. More severe damage to DNA, lipids and proteins can
occur if hydrogen peroxide is not removed and forms hydroxyl radicals by the Fenton reaction.
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Fig. 4. The relationship of induction of MnSOD to the redox state of skin fibroblasts as measured by lactate to pyruvate ratio in patients
with complex I deficiency. Plots of MnSOD quantity versus LrP ratio showed an inverse relationship for patient cell lines with complex I
deficiency. For patient fibroblast mitochondria with pyruvate carboxylase, pyruvate dehydrogenase, complex III or complex IV there was
w xno correlation. Data taken from Ref. 63 .
redox state in these cell lines but was only seen in
Complex I deficiency and not in other respiratory
chain defects involving Complex III or Complex IV
w x  .63 Fig. 4 .
We hypothesized that oxygen radical production is
increased when Complex I activity is compromised.
However, the observed superoxide production rates
are modulated by the variant induction of MnSOD
Fig. 5. The reciprocal relationship between superoxide production and manganese superoxide dismutase for mitochondria prepared from
patient skin fibroblasts. Manganese superoxide dismutase measured by immunoreactivity is plotted as a function of the observed rate of
w xsuperoxide production as measured by lucigenin fluorescence. Data is from Ref. 63 .
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which decreases the rate, sometimes below that seen
in control fibroblast mitochondria. The variant induc-
tion of MnSOD in turn we show is most likely a
function of the change in redox state of the cell
experienced as a result of the Complex I defect. Thus
a plot of MnSOD present in mitochondria as a func-
tion of redox state estimated by LrP ratio is a linear
 .one Fig. 4 . Plots of MnSOD quantity versus super-
oxide production showed an inverse relationship for
w x most conditions with Complex I deficiency 63 Fig.
.5 .
3.6. Relationship of MnSOD status to clinical
se˝erity
What was important from the patient prognostic
point of view is that while we could find little
correlation between the severity of symptoms and the
severity of the defect in Complex I activity, there was
a definite tendency for the patients with high induc-
tion of MnSOD to be more severely affected than
w xthose with a low induction 63 . This suggests the
following scenario: mutations in Complex I subunits
are of two types—those that block the flow of elec-
trons before the first quinone reduction centre and
those that block after. Those that block before will
result in impairment solely of oxidative phosphoryla-
tion while those that block after will result in both
impairment of oxidative phosphorylation and genera-
tion of excess superoxide. If the superoxide produc-
tion is high and the redox state is fairly reduced,
induction of MnSOD occurs. This produces excess
hydrogen peroxide which can in turn act as a sub-
 .strate for the Fenton reaction Fig. 3 . The final result
is the production of damaging hydroxyl radicals which
in affected individuals leads to high rates of morbid-
Fig. 6. The mitochondrial permeability transition and bcl-2. The adenine nucleotide translocator in the inner mitochondrial membrane
undergoes a reconfiguration triggered by oxygen free radicals or low ATP or increased Ca2q so that a pore develops allowing solutes to
exit from the matrix space. The transition is prevented by cyclosporin A so it is thought to involve a cis–trans prolidyl transpeptidase
 .cyclophilin . The transition is also prevented by the activity of the bcl-2 protein. This protein is anchored in the outer mitochondrial
membrane at its C-terminus. Bcl-2 forms dimers with itself or with the bax protein and the bcl-2 dimers bind the apaf-1 protein. When
bax is in excess the pore formation is favoured, when bound to bcl-2 it is prevented. Pore opening is thought to be an early event in
apoptotic cell death. Concomitant with the opening of the pore or as a result of it, cytochrome c is released to the cytosol where in
conjunction with the apaf-1 protein it activates Caspase 3. This in turn promotes apoptosis by precipitating nuclear condensation and
inactivation of DNA repair enzymes.
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ity and mortality. When we tested this hypothesis in
whole cells it was found that high levels of MnSOD
did indeed lead to high rates of hydroxyl radical
w xproduction and lipid peroxidation 69 .
3.7. Bcl-2 expression in Complex I deficiency
The bcl-2 family of proteins is intimately associ-
w xated with the process of apoptosis 93,94 . Apoptosis
is a form of ‘cellular suicide’ which comes into play
usually when a cell is not needed morphologically or
when a cell is damaged to a point where it will not
w xrecover 94,95 . Such mechanisms are also operative
when cells are attacked by viruses so that the cell can
be put out of action before replicating large numbers
of virus particles. One of the major pathways for
induction of apoptosis is set in motion by a mito-
chondrial event. Evidence is growing that one of the
early events in apoptotic cell death involves the
 .opening of the mitochondrial transition pore MTP
perhaps triggered by a phosphorylation event or by
w xaction of oxygen free radicals 94,95 . The function-
ing of the transition pore complex is thought to be
mediated by a major change in the configuration of
the adenine nucleotide translocator protein, which
occurs when Dc is decreased or oxygen free radi-
2q  .cals, high levels of Ca or low ATP )1 mM
conditions prevail such that mitochondrial solutes can
w x  .leak out 94–97 Fig. 6 . This pore opening is sensi-
tive to Cyclosporin A and thus involves a cis–trans
Peptidyl-prolyl isomerase. Bcl-2 somehow delays the
opening of these MTPs by some process unknown,
perhaps delaying the decay of the membrane poten-
w xtial 96,97 . Further research is required to fully
understand the connection between free radical ap-
pearance, which seems to trigger opening of MTP,
bcl-2 expression and apoptosis.
This opening of the MTP also seems to be associ-
ated with a process that allows cytochrome c to
dissociate from the inner membrane to leak in to the
w xcytosol 96 . Once the MTP has occurred and cy-
tochrome c is released into the cytosol, in conjunc-
w xtion with the Apaf-1 protein 98 it activates the
 .cytosolic Caspases ICE proteases which proteolyti-
cally cut DNA repair enzymes such as PARP and
w xnuclear DNA undergoes condensation 96,98 and
degradation. This cascade can be prevented by the
bcl-2 gene product, a protein which is attached to the
outer membrane of mitochondria. The bcl-2 protein
itself is thought to be protective under most circum-
stances except under certain conditions of phosphory-
w xlation 99 . Several important observations have sug-
gested a role for mitochondria in the control of
w xapoptosis 100 . The bcl-2 protein is well situated in
this regard as a protective agent. It is localized to the
w xouter mitochondrial membrane 101,102 , and with-
 .out its C-terminal transmembrane TM domain,
which acts as a membrane anchor, the anti-apoptosis
w xrole of bcl-2 is non-functional 103 . Increased ex-
pression of bcl-2 prevents the release of cytochrome
c and has effects on the release of Ca2q from the
w xmitochondria 104,105 which in turn delay or pre-
vent induction of the mitochondrial permeability tran-
sition.
Oxygen free radical production by mitochondria
induced either by cytokines or by cellular damage
may be one of the major triggers of the apoptotic
w xprocess 104–107 . Increased apoptotic death can be
induced by free radical amplifiers such as menadione
w x63 . Paradoxically bcl-2 appears to be induced by
increased oxygen free radical production at the same
time as it has a diminishing effect on apoptosis
w x104–107 . Bcl-2 may also decrease production of
w xfree radicalsin certain circumstances 105 . Thus bcl-2
w xis induced by the Complex I inhibitor rotenone 108
and is also increased in cells with respiratory chain
w xdefects involving Complex I 109,110 . It is espe-
cially increased in cell lines with poor MnSOD in-
Fig. 7. Mechanisms for the induction and modulation of man-
ganese superoxide dismutase and bcl-2. Superoxide produced as a
result of respiratory chain defects or ischemiarreperfusion injury
will induce either MnSOD if the NADrNADH redox state is
.changed or bcl-2. Alternatively cytokines through a protein
kinase C-dependant mechanism can induce MnSOD or modulate
bcl-2 by phosphorylation.
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w xduction 109 . MnSOD induction by superoxide and
redox state is probably mediated through one of the
w xspecies of protein kinase C 111 while bcl-2 induc-
tion and phosphorylation proceeds through a similar
though different route involving the stress activated
w xkinases 112–114 . Thus as with the protective up-
regulation of MnSOD, the bcl-2 gene family may be
induced to rescue these cells from the continuous
exposure to increased ROS and their potential to
induce cellular damage. The difference between the
two systems, bcl-2 and MnSOD, seems to depend on
relative changes in redox state such that cell lines
showing big increases of superoxide with small dis-
turbances of the NADrNADH ratio have a higher
 .tendency to induce bcl-2 Fig. 7 .
4. Conclusion
Many groups are trying to find the mutations in the
nuclear and mitochondrial genomes that give rise to
Complex I deficiency and that may give some insight
into the molecular etiology of the pathogenetic mech-
anisms involved. At the same time information about
the defense mechanisms that operate in these com-
promised cells is beginning to emerge that may be
actually as useful as knowledge of the mutation in
terms of future attempts at therapy of these disorders.
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